Adverse events (World Health Organization grades 3 to 5) after the start of induction therapy
| . | IDR group, no. of patients (%) . | DNR group, no. of patients (%) . | P . |
|---|---|---|---|
| Sepsis | 46 (8.7) | 26 (4.9) | .021 |
| Early death* | 25 (4.7) | 11 (2.1) | .026 |
| Bleeding | 19 (3.6) | 23 (4.4) | .532 |
| Febrile neutropenia | 416 (78.2) | 406 (77.4) | .761 |
| Acute cardiac toxicity | 10 (1.9) | 4 (0.8) | .112 |
| Late-onset cardiac failure | 2 (0.38) | 2 (0.38) | .998 |
| . | IDR group, no. of patients (%) . | DNR group, no. of patients (%) . | P . |
|---|---|---|---|
| Sepsis | 46 (8.7) | 26 (4.9) | .021 |
| Early death* | 25 (4.7) | 11 (2.1) | .026 |
| Bleeding | 19 (3.6) | 23 (4.4) | .532 |
| Febrile neutropenia | 416 (78.2) | 406 (77.4) | .761 |
| Acute cardiac toxicity | 10 (1.9) | 4 (0.8) | .112 |
| Late-onset cardiac failure | 2 (0.38) | 2 (0.38) | .998 |
IDR indicates idarubicin; and DNR, daunorubicin.
Death within 60 days after the start of induction therapy.